|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Preusser M, de Ribaupierre S, Wöhrer A,
Erridge SC, Hegi M, Weller M and Stupp R: Current concepts and
management of glioblastoma. Ann Neurol. 70:9–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilson TA, Karajannis MA and Harter DH:
Glioblastoma multiforme: State of the art and future therapeutics.
Surg Neurol Int. 5:642014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2006–2010. Neuro Oncol.
15(Suppl 2): ii1–ii56. 2013. View Article : Google Scholar :
|
|
5
|
Bai RY, Staedtke V and Riggins GJ:
Molecular targeting of glioblastoma: Drug discovery and therapies.
Trends Mol Med. 17:301–312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang G, Li LT, Xin Y, Zhang L, Liu YQ and
Zheng JN: Strategies to improve the killing of tumors using
temozolomide: Targeting the DNA repair protein MGMT. Curr Med Chem.
19:3886–3892. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bei R, Marzocchella L and Turriziani M:
The use of temozolomide for the treatment of malignant tumors:
Clinical evidence and molecular mechanisms of action. Recent
Patents Anticancer Drug Discov. 5:172–187. 2010. View Article : Google Scholar
|
|
8
|
Begg AC, Stewart FA and Vens C: Strategies
to improve radiotherapy with targeted drugs. Nat Rev Cancer.
11:239–253. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eich M, Roos WP, Nikolova T and Kaina B:
Contribution of ATM and ATR to the resistance of glioblastoma and
malignant melanoma cells to the methylating anticancer drug
temozolo-mide. Mole Cancer Ther. 12:2529–2540. 2013. View Article : Google Scholar
|
|
10
|
Nathanson DA, Gini B, Mottahedeh J,
Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et
al: Targeted therapy resistance mediated by dynamic regulation of
extrachro-mosomal mutant EGFR DNA. Science. 343:72–76. 2014.
View Article : Google Scholar :
|
|
11
|
Vlachostergios PJ, Hatzidaki E, Befani CD,
Liakos P and Papandreou CN: Bortezomib overcomes MGMT-related
resistance of glioblastoma cell lines to temozolomide in a
schedule-dependent manner. Invest New Drugs. 31:1169–1181. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Williams TM, Flecha AR, Keller P, Ram A,
Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A,
et al: Cotargeting MAPK and PI3K signaling with concurrent
radiotherapy as a strategy for the treatment of pancreatic cancer.
Mol Cancer Ther. 11:1193–1202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang G, Li X, Huang F, Zhao J, Ding H,
Cunningham C, Coad JE, Flynn DC, Reed E and Li QQ: Antitumor effect
of beta-elemene in non-small-cell lung cancer cells is mediated via
induction of cell cycle arrest and apoptotic cell death. Cell Mol
Life Sci. 62:881–893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li QQ, Wang G, Liang H, Li JM, Huang F,
Agarwal PK, Zhong Y and Reed E: β-Elemene promotes
cisplatin-induced cell death in human bladder cancer and other
carcinomas. Anticancer Res. 33:1421–1428. 2013.PubMed/NCBI
|
|
15
|
Yu Z, Wang R, Xu L, Xie S, Dong J and Jing
Y: β-Elemene piperazine derivatives induce apoptosis in human
leukemia cells through downregulation of c-FLIP and generation of
ROS. PLoS One. 6:e158432011. View Article : Google Scholar
|
|
16
|
Li QQ, Lee RX, Liang H, Wang G, Li JM,
Zhong Y and Reed E: β-elemene enhances susceptibility to cisplatin
in resistant ovarian carcinoma cells via downregulation of ERCC-1
and XIAP and inactivation of JNK. Int J Oncol. 43:721–728.
2013.PubMed/NCBI
|
|
17
|
Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ
and Xu YH: Anti-tumor effect of beta-elemene in glioblastoma cells
depends on p38 MAPK activation. Cancer Lett. 264:127–134. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fischel JL, Formento P and Milano G:
Epidermal growth factor receptor double targeting by a tyrosine
kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab).
Impact on cell growth and molecular factors. Br J Cancer.
92:1063–1068. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li QQ, Wang G, Huang F, Li JM, Cuff CF and
Reed E: Sensitization of lung cancer cells to cisplatin by
β-elemene is mediated through blockade of cell cycle progression:
Antitumor efficacies of β-elemene and its synthetic analogs. Med
Oncol. 30:4882013. View Article : Google Scholar
|
|
20
|
Zou K, Tong E, Xu Y, Deng X and Zou L:
Down regulation of mammalian target of rapamycin decreases
HIF-1alpha and survivin expression in anoxic lung adenocarcinoma
A549 cell to elemene and/or irradiation. Tumour Biol. 35:9735–9741.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou HY, Xu YH and Luo QZ: The clinical
studies of β-elemene’s anti-tumor effect on gliomas. J Med J
Liaoning. 17:189–191. 2003.
|
|
22
|
Zhang H, Xu F, Xie T, Jin H and Shi L:
β-elemene induces glioma cell apoptosis by downregulating survivin
and its interaction with hepatitis B X-interacting protein. Oncol
Rep. 28:2083–2090. 2012.PubMed/NCBI
|
|
23
|
Zhao YS, Zhu TZ, Chen YW, Yao YQ, Wu CM,
Wei ZQ, Wang W and Xu YH: Β-elemene inhibits Hsp90/Raf-1 molecular
complex inducing apoptosis of glioblastoma cells. J Neurooncol.
107:307–314. 2012. View Article : Google Scholar
|
|
24
|
Barlow C, Brown KD, Deng CX, Tagle DA and
Wynshaw-Boris A: Atm selectively regulates distinct p53-dependent
cell-cycle checkpoint and apoptotic pathways. Nat Genet.
17:453–456. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matsuoka S, Rotman G, Ogawa A, Shiloh Y,
Tamai K and Elledge SJ: Ataxia telangiectasia-mutated
phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA.
97:10389–10394. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Biddlestone-Thorpe L, Sajjad M, Rosenberg
E, Beckta JM, Valerie NC, Tokarz M, Adams BR, Wagner AF, Khalil A,
Gilfor D, et al: ATM kinase inhibition preferentially sensitizes
p53-mutant glioma to ionizing radiation. Clin Cancer Res.
19:3189–3200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Golding SE, Rosenberg E, Adams BR,
Wignarajah S, Beckta JM, O’Connor MJ and Valerie K: Dynamic
inhibition of ATM kinase provides a strategy for glioblastoma
multiforme radiosensitiza-tion and growth control. Cell Cycle.
11:1167–1173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mukherjee B, McEllin B, Camacho CV,
Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B,
Madden C, Maher E, et al: EGFRvIII and DNA double-strand break
repair: A molecular mechanism for radioresistance in glioblastoma.
Cancer Res. 69:4252–4259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khalil A, Morgan RN, Adams BR, Golding SE,
Dever SM, Rosenberg E, Povirk LF and Valerie K: ATM-dependent ERK
signaling via AKT in response to DNA double-strand breaks. Cell
Cycle. 10:481–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Viniegra JG, Martínez N, Modirassari P,
Hernández Losa J, Parada Cobo C, Sánchez-Arévalo Lobo VJ, Aceves
Luquero CI, Alvarez-vallina L, Ramón y Cajal S, Rojas JM, et al:
Full activation of PKB/Akt in response to insulin or ionizing
radiation is mediated through ATM. J Biol Chem. 280:4029–4036.
2005. View Article : Google Scholar
|
|
31
|
Golding SE, Rosenberg E, Neill S, Dent P,
Povirk LF and Valerie K: Extracellular signal-related kinase
positively regulates ataxia telangiectasia mutated, homologous
recombination repair, and the DNA damage response. Cancer Res.
67:1046–1053. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Munshi A and Ramesh R: Mitogen-activated
protein kinases and their role in radiation response. Genes Cancer.
4:401–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
